Tag Archives: in

EXCLUSIVE Amazon, Tata say Indian govt e-commerce rules will hit businesses -sources

NEW DELHI, July 3 (Reuters) – Amazon.com Inc (AMZN.O) and India’s Tata Group warned government officials on Saturday that plans for tougher rules for online retailers would have a major impact on their business models, four sources familiar with the discussions told Reuters.

At a meeting organised by the consumer affairs ministry and the government’s investment promotion arm, Invest India, many executives expressed concerns and confusion over the proposed rules and asked that the July 6 deadline for submitting comments be extended, said the sources.

The government’s tough new e-commerce rules announced on June 21 aimed at strengthening protection for consumers, caused concern among the country’s online retailers, notably market leaders Amazon and Walmart Inc’s (WMT.N) Flipkart.

New rules limiting flash sales, barring misleading advertisements and mandating a complaints system, among other proposals, could force the likes of Amazon and Flipkart to review their business structures, and may increase costs for domestic rivals including Reliance Industries’ (RELI.NS) JioMart, BigBasket and Snapdeal. read more

Amazon argued that COVID-19 had already hit small businesses and the proposed rules will have a huge impact on its sellers, arguing that some clauses were already covered by existing law, two of the sources said.

The sources asked not to be named as the discussions were private.

The proposed policy states e-commerce firms must ensure none of their related enterprises are listed as sellers on their websites. That could impact Amazon in particular as it holds an indirect stake in at least two of its sellers, Cloudtail and Appario.

On that proposed clause, a representative of Tata Sons, the holding company of India’s $100 billion Tata Group, argued that it was problematic, citing an example to say it would stop Starbucks (SBUX.O) – which has a joint-venture with Tata in India – from offering its products on Tata’s marketplace website.

The Tata executive said the rules will have wide ramifications for the conglomerate, and could restrict sales of its private brands, according to two of the sources.

Tata declined to comment.

The sources said that a consumer ministry official argued that the rules were meant to protect consumers and were not as strict as those of other countries. The ministry did not respond to a request for comment.

A Reliance executive agreed that the proposed rules would boost consumer confidence, but added that some clauses needed clarification.

Reliance did not respond to request for comment.

The rules were announced last month amid growing complaints from India’s brick-and-mortar retailers that Amazon and Flipkart bypass foreign investment law using complex business strcutures. The companies deny any wrongdoing.

A Reuters investigation in February cited Amazon documents that showed it gave preferential treatment to a small number of its sellers and bypassed foreign investment rules. Amazon has said it does not give favourable treatment to any seller.

The government will soon issue certain clarifications on the foreign investment rules, Indian commerce minister Piyush Goyal told reporters on Friday.

Reporting by Aditya Kalra in New Delhi;
Editing by Euan Rocha and Louise Heavens

Our Standards: The Thomson Reuters Trust Principles.

Read original article here

India’s Bharat Biotech says vaccine 93.4% effective against severe COVID-19

July 3 (Reuters) – Phase-III trials of a vaccine made by India’s Bharat Biotech showed it was 93.4% effective against severe symptomatic COVID-19, the firm said on Saturday, a finding that could boost people’s acceptance of Covaxin.

The data demonstrated 65.2% protection against the Delta variant, first identified in India, that led to a surge in infections in April and May, and the world’s highest daily death tolls.

India’s homegrown vaccine also showed effectiveness of 77.8% against symptomatic COVID-19 in the trial.

Last month, vaccine maker AstraZeneca Plc (AZN.L) also said its vaccine was effective against the Delta and Kappa variants, citing a study.

India has been administering the AstraZeneca vaccine, made domestically by the Serum Institute of India, which said last month it planned to step up monthly production from July, to nearly 100 million doses.

Bharat Biotech now estimates it will make 23 million doses a month.

The Phase-III data came as Ocugen Inc (OCGN.O), which is co-developing Covaxin with Bharat Biotech for the U.S. market, prepares to file a request for full U.S. approval.

India, with a tally of 30.45 million infections, is the second most affected nation after the United States, with 33 million. The south Asian nation’s death toll has now crossed 400,000.

Reporting by Maria Ponnezhath in Bengaluru; Editing by Clarence Fernandez

Our Standards: The Thomson Reuters Trust Principles.

Read original article here

CureVac COVID-19 vaccine records only 48% efficacy in final trial readout

A dose of CureVac vaccine or a placebo is seen during a study by the German biotech firm CureVac as part of a testing for a new vaccine against the coronavirus disease (COVID-19), in Brussels, Belgium March 2, 2021. REUTERS/Yves Herman

June 30 (Reuters) – CureVac (5CV.DE) said its COVID-19 vaccine was 48% effective in the final analysis of its pivotal mass trial, only marginally better than the 47% reported after an initial read-out two weeks ago.

The German biotech firm said that efficacy, measured by preventing symptomatic disease, was slightly better at 53% when excluding trial participants older than 60 years, an age group that is by far the most severely affected.

CureVac said on June 16 its COVID-19 vaccine, known as CVnCoV, proved only 47% effective in an initial trial read-out and that new variants had proved a headwind, denting investor confidence in its ability to take on rival shots.

That wiped billions of euros from its market value.

Wednesday’s news sent U.S.-listed shares of the company 10.2% lower to $66 after the bell.

Late-stage trials of BioNTech/Pfizer (22UAy.DE), (PFE.N) and Moderna (MRNA.O) vaccines, which like CureVac’s are based on mRNA technology, had efficacy rates of well above 90% across all age groups but took place when the original version of the coronavirus was dominant.

Data on their products have, however, so far suggested only somewhat weaker protection against new variants.

The CureVac study, which involved about 40,000 adult volunteers in Europe and Latin America, showed that efficacy was 77% in the age group below 60 years of age when considering only moderate to severe symptoms and excluding mild cases.

CureVac said it had sent the data to the European Medicines Agency (EMA) as part of an ongoing dialogue with the EU drugs regulator.

CureVac previously said that the regulatory hurdle was 50% efficacy in principle but that various other considerations would come into play.

“In this final analysis, CVnCoV demonstrates a strong public health value in fully protecting study participants in the age group of 18 to 60 against hospitalization and death and 77% against moderate and severe disease – an efficacy profile, which we believe will be an important contribution to help manage the COVID-19 pandemic and the dynamic variant spread,” said Chief Executive Officer Franz-Werner Haas.

CureVac had registered 228 infections overall for the final analysis, after 134 cases for the interim analysis.

Public health representatives across the globe are pushing for a fast deployment of available vaccines to counter highly contagious mutations of COVID-19 such as the Delta variant that first emerged in India.

The EMA has said it would not impose a 50% efficacy threshold for vaccines and that full trial data was necessary for it to make a sound assessment on the benefits and risks of a shot. read more

Under CureVac’s only major supply deal for the product tested in the trial, the European Union secured up to 405 million doses of the vaccine in November, of which 180 million are optional.

In a bet on CureVac’s technology, Britain placed a conditional 50 million dose order in February on yet-to-be-developed vaccines that build on the product tested in the trial. read more

CureVac had lined up a network of manufacturing partners including Celonic Group of Switzerland, Novartis (NOVN.S), Bayer (BAYGn.DE), Fareva, Wacker (WCHG.DE) and Rentschler Biopharma SE.

($1 = 0.8377 euros)

Reporting by Ludwig Burger, Editing by Rosalba O’Brien

Our Standards: The Thomson Reuters Trust Principles.

Read original article here

Brazil to suspend Indian COVID-19 vaccine deal as graft claims probed

RIO DE JANEIRO, June 29 (Reuters) – Brazil will suspend a $324-million contract for COVID-19 vaccine from India that has mired President Jair Bolsonaro in accusations of irregularities, the health minister said on Tuesday, following guidance by the federal comptroller, the CGU.

The deal to buy 20 million doses of Bharat Biotech’s Covaxin shot has become a headache for Bolsonaro after whistleblowers went public with alleged irregularities. One health ministry official said he alerted the president about his concerns.

Bolsonaro, whose popularity has faded as Brazil’s COVID-19 death toll climbed past 500,000, has denied any wrongdoing, saying on Monday he was not aware of any irregularities.

But thorny questions persist, and may pose problems for him ahead of next year’s presidential vote.

Health Minister Marcelo Queiroga told a news conference his team would investigate the accusations during the suspension.

“According to the preliminary analysis of the CGU, there are no irregularities in the contract but, for compliance, the health ministry chose to suspend the contract,” the ministry said in a statement.

CNN Brasil had earlier reported that the ministry had decided to cancel the contract.

Brazilian federal prosecutors have opened an investigation, citing comparatively high prices of about $15 a dose, quick talks and pending regulatory approvals as red flags.

In a statement, Bharat Biotech said it had followed a “step-by-step” approach for the regulatory approval and supply contract of its vaccine in Brazil, and had not received advance payments from the health ministry.

It added that the pricing of Covaxin had been set between $15 and $20 a dose for supplies to governments outside India.

The deal is also being probed by a Senate panel investigating Brazil’s handling of the pandemic.

One leading opposition senator on the panel, Randolfe Rodrigues, filed a formal criminal complaint against Bolsonaro with the Supreme Court on Monday.

He asked the court to investigate why Bolsonaro “did not take any action after being notified of the existence of a giant corruption scheme in the Health Ministry.”

($1=4.9403 reais)

Reporting by Gabriel Stargardter and Pedro Fonseca; Additional reporting by Uday Sampath in Bengaluru; Editing by Bill Berkrot and Clarence Fernandez

Our Standards: The Thomson Reuters Trust Principles.

Read original article here

Twitter faces three police cases amid growing challenges in India

LUCKNOW, India, June 29 (Reuters) – Police in India have registered three new cases against Twitter Inc(TWTR.N) for allegedly hurting sentiments and promoting child pornography, marking an escalation in the row between the U.S. firm and Indian authorities.

Police in the states of Uttar Pradesh and Madhya Pradesh have named Twitter India chief Manish Maheshwari in complaints afterthe politically sensitive regions were depicted outside a map of India on its careers website.

Late on Tuesday, police in the capital New Delhi said in a statement they have registered a case against Twitter for “availability of child sexual abuse and child pornographic material” on its platform.

Twitter did not comment on cases related to India’s map. On the New Delhi case, Twitter said it has a zero tolerance policy for child sexual exploitation.

The police cases come as Twitter faces a public relations nightmare and a backlash from Prime Minister Narendra Modi’s federal government that has in recent weeks repeatedly criticized it for not complying with a new set of IT rules.

The tussle, coupled with discontent over the regulatory scrutiny of other U.S. tech firms like WhatsApp and Amazon, has upset the business environment in a key growth markets, so much so that some companies are rethinking expansion plans. read more

The latest complaints against Twitter were triggered following an uproar on social media after a map on Twitter’s careers page showed Jammu and Kashmir, claimed by both India and Pakistan, as well as the Buddhist enclave of Ladakh, outside India. As of Tuesday, the map was no longer visible on its site.

The Twitter logo is displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., September 28, 2016. REUTERS/Brendan McDermid

Read More

“This has hurt my sentiments and those of the people of India,” Praveen Bhati, a leader of a hardline Hindu group Bajrang Dal in Uttar Pradesh, said in the complaint which was reviewed by Reuters. He also called it an act of treason.

The child pornography case in New Delhi was registered after India’s National Commission for Protection of Child Rights wrote to police saying it had received a complaint about online threats against a minor girl, and found pornographic material on Twitter, according to a letter written by the rights group to police.

“Investigation has been taken up,” the Delhi police statement said.

The cases are set to amplify Twitter’s troubles in India. Technology minister Ravi Shankar Prasad has criticised Twitter for its failure to abide by the IT rules in recent weeks, which came into effect in May. read more

Companies such as Twitter must now appoint a chief compliance officer, a grievance officer and another executive to liaise with law enforcement and the government on legal requests. LinkedIn job postings show the three positions are open at Twitter.

Non-compliance with those rules means Twitter may no longer enjoy the legal privilege in India that allowed it to not be held liable for user-generated content, lawyers and government sources say. Activists however defend Twitter, saying only courts can arrive at that decision.

Twitter India chief Maheshwari is battling another police case where he has been summoned to answer allegations that include inciting “hate and enmity” between Hindu and Muslim communities in relation to a video that went viral on its platform. A state court last week said no “coercive action” should be taken against Maheshwari in the case. read more

Reporting by Saurabh Sharma and Sankalp Phartiyal; Additional reporting by Abhirup Roy; Editing by Aditya Kalra, Edwina Gibbs and Nick Macfie

Our Standards: The Thomson Reuters Trust Principles.

Read original article here

Quake of magnitude 6 strikes India’s Assam, damages some buildings

An earthquake of magnitude 6 struck India’s rugged northeastern state of Assam on Wednesday, causing cracks in the walls and floors of some structures, but no immediate casualties were reported.

The quake hit at a depth of 34 km (21 miles) near the town of Dhekiajuli, 140 km (86 miles) north of the main city of Guwahati, the United States Geological Survey said.

“This earthquake was the biggest I can remember, there was first a big jolt and then a smaller one,” said a police official in the town. “We did not receive any distress calls, but people did run out of their homes.”

People streamed into the streets for fear of fresh tremors, with some saying the quake left cracks in their homes.

“Our entire multi-storied apartment has witnessed massive damage with roofs and walls caving in,” said Subham Hazarika, a businessman living in an upmarket apartment in Guwahati. “Luckily no one got injured.”

Strong tremors repeatedly struck other northeastern areas and the neighbouring mountainous region of Bhutan.

“We don’t have reports of any casualties but we are seeing images and visuals of extensive damage,” Health Minister Himanta Biswa Sarma told Reuters.

Earlier, the European Mediterranean Seismological Centre (EMSC) had put the quake’s magnitude at 6.2.

India’s disaster management officials were assessing reports of destruction and casualties, said one of the officials, who sought anonymity.

“I pray for the well-being of all and urge everyone to stay alert,” Chief Minister Sarbananda Sonowal told Reuters television partner ANI.

Our Standards: The Thomson Reuters Trust Principles.

Read original article here

Modi appeals to keep Hindu festival symbolic as India’s COVID-19 infections surge

Indian Prime Minister Narendra Modi on Saturday appealed to devotees to keep a key Hindu festival symbolic, amid worries about the spread of COVID-19 infections as the country reported more than 200,000 new cases for a third straight day.

Criticism has mounted over the Indian government’s handling of the health crisis, as religious festivals and election rallies continue despite reports of shortages of hospital beds, oxygen cylinders and vaccination doses. read more

India reported 234,692 COVID-19 infections over the last 24 hours, taking the total number of cases to nearly 14.5 million, second only to the United States.

Deaths from the disease rose by 1,341 to 175,649.

After hundreds of thousands of ascetics and devout Hindus gathered for several days along the banks of the Ganges for a religious festival Kumbh Mela, Modi on Saturday called for restraint, saying on Twitter the festival should now be kept “symbolic”.

Responding to Modi’s appeal, one of the religious leaders Swami Avdheshanand urged devotees to not gather in large numbers. Devout Hindus believe bathing in the holy Ganges absolves people of sins, and during the Kumbh Mela, brings salvation from the cycle of life and death.

Those returning to Mumbai in western Maharashtra state from the Kumbh Mela will have quarantine in hotels, Mumbai’s mayor Kishori Pednekar said. Maharashtra accounts for quarter of India’s coronavirus cases and is the worst hit region.

Experts have warned about the spread of more contagious variants of the disease, especially during large-scale gatherings for religious festivals and political rallies.

On Saturday, Modi was scheduled to hold two rallies in eastern state of West Bengal where state polls are ongoing. In recent weeks, such rallies have attracted thousands of people, few of whom follow COVID-19 safety protocols.

“Stop spreader rallies,” the Times of India said in an editorial on Saturday, adding: “Business as usual is an unaffordable luxury until this virus is conclusively tamed.”

India’s daily COVID-19 vaccinations have slowed from their record high early this month and many state governments have requested more doses.

Federal Health Minister Harsh Vardhan assured states there were no shortages and 11.6 million doses would be made available in a week, adding that 125 million doses have already been administered.

Some state governments in India have raised concerns over hoarding and black marketing of anti-viral drug Remdesivir. read more

Nawab Malik, a minister from Maharashtra, accused Modi’s federal government on Twitter for restricting Remdesivir supplies to the state. A minister in Modi’s cabinet, Mansukh Mandaviya, denied the allegation, saying adequate supplies were being arranged.

After imposing one of the world’s strictest lockdowns for nearly three months last year, India’s government relaxed almost all curbs by the beginning of 2021, although many regions have now introduced localised restrictions.

“This is Narendra Modi’s biggest crisis yet. It is bigger than any security threat, external or internal, or even the economic attrition of 2020,” prominent editor and political commentator Shekhar Gupta wrote in a column on Saturday.

Our Standards: The Thomson Reuters Trust Principles.

Read original article here

UFC Vegas 22: Brunson vs Holland Weigh-in – UFC – Ultimate Fighting Championship

  1. UFC Vegas 22: Brunson vs Holland Weigh-in UFC – Ultimate Fighting Championship
  2. UFC Vegas 22: Brunson vs. Holland Preview Show LIVE Stream – MMA Fighting MMAFightingonSBN
  3. UFC Fight Night predictions — Derek Brunson vs. Kevin Holland: Fight card, odds, start time, live stream CBS Sports
  4. Despite wanting a top-ranked opponent, Derek Brunson happy to oblige Kevin Holland’s call-out Yahoo Sports
  5. UFC Main Card Best Bets: DraftKings Sportsbook Betting Odds, Picks, Preview for UFC Fight Night: Brunson vs. … DraftKings Nation
  6. View Full Coverage on Google News

Read original article here

UFC Vegas 21: Weigh-in Faceoffs – UFC – Ultimate Fighting Championship

  1. UFC Vegas 21: Weigh-in Faceoffs UFC – Ultimate Fighting Championship
  2. UFC Fight Night 187 predictions: Edwards or Muhammad in welterweight showdown? MMA Junkie
  3. Jorge Masvidal, Darren Till, Dana White and Michael Bisping on ‘scary’ Leon Edwards who Dan Hardy says is d… talkSPORT.com
  4. Belal Muhammad will slap the sh*t out of ‘evil’ Colby Covington if they ever cross paths in the street MMA Mania
  5. UFC Main Card Best Bets: DraftKings Sportsbook Betting Odds, Picks, Preview for UFC Fight Night: Edwards vs. … DraftKings Nation
  6. View Full Coverage on Google News

Read original article here